

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-17. (CANCELLED)

18. (New) A composition comprising the pure form of the protease activating blood clotting factor VII and one or more substances chosen from:

- a) complexing agents of divalent ions;
- b) amino acids;
- c) sugars;
- d) detergents;
- e) alcohols;
- f) albumin;
- g) gelatin;
- h) fibronectin;
- i) vitronectin;
- j) reductants; and
- k) protease inhibitors;

wherein the amino acid sequence of the protease comprises the following peptide sequences: IYGGFKSTAGKHP (SEQ ID NO:1), LLESLDAPDXTDP (SEQ ID NO:2), EFHEQSFRVEKI (SEQ ID NO:3), and SKFTXAXPXQFK (SEQ ID NO:4), wherein X denotes an unidentified amino acid.

19. (New) The composition according to claim 18, comprising one or more complexing agents of divalent ions chosen from one or more of EDTA, EGTA, and citrate.

20. (New) The composition according to claim 19, wherein the one or more complexing agents of divalent ions comprises EDTA.

21. (New) The composition according to claim 19, further comprising one or more substances chosen from amino acids, protease inhibitors, and albumin.
22. (New) The composition according to claim 21, comprising at least one amino acid comprising arginine.
23. (New) The composition according to claim 21, comprising at least one protease inhibitor comprising aprotinin.
24. (New) The composition according to claim 18, comprising one or more amino acids chosen from one or more of glutamate, arginine, lysine, and glycine.
25. (New) The composition according to claim 18, comprising one or more sugars chosen from one or more of glucose, arabinose, mannose, and mannitol.
26. (New) The composition according to claim 18, comprising one or more alcohols chosen from one or both of ethylene glycol and polyethylene glycol.
27. (New) The composition according to claim 18, comprising one or more reductants chosen from one or more of dithiothreitol, mercaptoethanol or cysteine.
28. (New) The composition according to claim 18, comprising one or more protease inhibitors chosen from one or more of aprotinin, α 2-antiplasmin, C1-esterase inhibitor, inter- α -trypsin inhibitor, and antithrombin III/heparin inhibitor.
29. (New) The composition according to claim 28, wherein the one or more protease inhibitors comprise aprotinin.
30. (New) The composition according to claim 28, further comprising one or more amino acids.

31. (New) The composition according to claim 28, further comprising albumin.
32. (New) The composition according to claim 18, wherein the composition acts as a biological test reagent.
33. (New) A composition comprising a pure form of a proenzyme for the protease activating blood clotting factor VII, optionally further comprising one or more substances chosen from:
- a) complexing agents of divalent ions;
 - b) amino acids;
 - c) sugars;
 - d) detergents;
 - e) alcohols;
 - f) albumin;
 - g) gelatin;
 - h) fibronectin;
 - i) vitronectin;
 - j) reductants; and
 - k) protease inhibitors;
- wherein the amino acid sequence of the protease comprises the following peptide sequences: IYGGFKSTAGKHP (SEQ ID NO:1), LLESLDAPDXTPD (SEQ ID NO:2), EFHEQSFRVEKI (SEQ ID NO:3), and SKFTXAXPXQFK (SEQ ID NO:4), wherein X denotes an unidentified amino acid.
34. (New) The composition according to claim 33, comprising one or more complexing agents of divalent ions chosen from one or more of EDTA, EGTA, and citrate.
35. (New) The composition according to claim 34, wherein the one or more complexing agents of divalent ions comprises EDTA.

36. (New) The composition according to claim 34, further comprising one or more substances chosen from amino acids, protease inhibitors, and albumin.
37. (New) The composition according to claim 36, comprising at least one amino acid comprising arginine.
38. (New) The composition according to claim 36, comprising at least one protease inhibitor comprising aprotinin.
39. (New) The composition according to claim 33, comprising one or more amino acids chosen from one or more of glutamate, arginine, lysine, and glycine.
40. (New) The composition according to claim 33, comprising one or more sugars chosen from one or more of glucose, arabinose, mannose, and mannitol.
41. (New) The composition according to claim 33, comprising one or more alcohols chosen from one or both of ethylene glycol and polyethylene glycol.
42. (New) The composition according to claim 33, comprising one or more reductants chosen from one or more of dithiothreitol, mercaptoethanol or cysteine.
43. (New) The composition according to claim 33, comprising one or more protease inhibitors chosen from one or more of aprotinin, α 2-antiplasmin, C1-esterase inhibitor, inter- α -trypsin inhibitor, and antithrombin III/heparin inhibitor.
44. (New) The composition according to claim 43, wherein the one or more protease inhibitors comprise aprotinin.
45. (New) The composition according to claim 43, further comprising one or more amino acids.

46. (New) The composition according to claim 43, further comprising albumin.
47. (New) The composition according to claim 33, wherein the composition acts as a biological test reagent.
48. (New) A composition comprising a mixture of a pure form of the protease activating blood clotting factor VII and a pure form of a proenzyme of said protease, and optionally further comprising one or more substances chosen from:
- a) complexing agents of divalent ions;
 - b) amino acids;
 - c) sugars;
 - d) detergents;
 - e) alcohols;
 - f) albumin;
 - g) gelatin;
 - h) fibronectin;
 - i) vitronectin;
 - j) reductants; and
 - k) protease inhibitors;
- wherein the amino acid sequence of the protease comprises the following peptide sequences: IYGGFKSTAGKHP (SEQ ID NO:1), LLESLDPDXTDP (SEQ ID NO:2), EFHEQSFRVEKI (SEQ ID NO:3), and SKFTXAXPXQFK (SEQ ID NO:4), wherein X denotes an unidentified amino acid.
49. (New) The composition according to claim 48, comprising one or more complexing agents of divalent ions chosen from one or more of EDTA, EGTA, and citrate.
50. (New) The composition according to claim 49, wherein the one or more complexing agents of divalent ions comprises EDTA.

51. (New) The composition according to claim 49, further comprising one or more substances chosen from amino acids, protease inhibitors, and albumin.
52. (New) The composition according to claim 51, comprising at least one amino acid comprising arginine.
53. (New) The composition according to claim 51, comprising at least one protease inhibitor comprising aprotinin.
54. (New) The composition according to claim 48, comprising one or more amino acids chosen from one or more of glutamate, arginine, lysine, and glycine.
55. (New) The composition according to claim 48, comprising one or more sugars chosen from one or more of glucose, arabinose, mannose, and mannitol.
56. (New) The composition according to claim 48, comprising one or more alcohols chosen from one or both of ethylene glycol and polyethylene glycol.
57. (New) The composition according to claim 48, comprising one or more reductants chosen from one or more of dithiothreitol, mercaptoethanol or cysteine.
58. (New) The composition according to claim 48, comprising one or more protease inhibitors chosen from one or more of aprotinin, α 2-antiplasmin, C1-esterase inhibitor, inter- α -trypsin inhibitor, and antithrombin III/heparin inhibitor.
59. (New) The composition according to claim 58, wherein the one or more protease inhibitors comprise aprotinin.
60. (New) The composition according to claim 58, further comprising one or more amino acids.

61. (New) The composition according to claim 58, further comprising albumin.
62. (New) The composition according to claim 48, wherein the composition acts as a biological test reagent.